Conivaptan Intravenous and Insulin aspart, recombinant Subcutaneous
Determining the interaction of Conivaptan Intravenous and Insulin aspart, recombinant Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: conivaptan
Brand name: Vaprisol
Synonyms: Conivaptan
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Conivaptan Intravenous-Insulin degludec
- Conivaptan Intravenous-Insulin Degludec (U-100) Prefilled Pens
- Conivaptan Intravenous-Insulin Degludec (U-100) Vials
- Conivaptan Intravenous-Insulin Degludec (U-200) Prefilled Pens
- Conivaptan Intravenous-Insulin degludec and liraglutide
- Conivaptan Intravenous-Insulin degludec and liraglutide Subcutaneous
- Insulin aspart, recombinant Subcutaneous-Conjugated estrogens
- Insulin aspart, recombinant Subcutaneous-Conjugated estrogens and bazedoxifene
- Insulin aspart, recombinant Subcutaneous-Conjugated estrogens and medroxyprogesterone
- Insulin aspart, recombinant Subcutaneous-Conjugated estrogens and medroxyprogesterone Oral
- Insulin aspart, recombinant Subcutaneous-Conjugated Estrogens Injection
- Insulin aspart, recombinant Subcutaneous-Conjugated estrogens Intravenous